Novartis Asks CHMP To Modify European Galvus Label To Recommend Lower Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients taking 50 mg dose of DPP-4 inhibitor had fewer liver enzyme elevations than those taking 100 mg, a profile Novartis wants to include in the label prior to EU launch.
You may also be interested in...
Novartis To Launch Galvus In EU With Lower Dosing Recommendation
EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.
Novartis To Launch Galvus In EU With Lower Dosing Recommendation
EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.